Non-alkolik yağlı karaciğer hastalığında kafein alımı ve karaciğer biyobelirteçleri arasındaki ilişki

Year 2023, Volume: 48 Issue: 1, 177 - 186, 31.03.2023

Kübra Uçar , Evrim Kahramanoğlu , Zeynep Göktaş

https://doi.org/10.17826/cumj.1171396

Cited By: 1

Abstract

Amaç: Non-alkolik yağlı karaciğer hastalığı (NAFLD), gelişmiş ülkelerde karaciğer enzimlerindeki yükselmenin en yaygın nedenidir. Bu çalışmanın amacı, NAFLD olan bireylerde kafein alımının karaciğer metabolizmasının bazı parametreleri üzerindeki etkilerini incelemektir.
Gereç ve Yöntem: Çalışmaya NAFLD tanısı almış 19-64 yaş arasında toplam 20 kadın ve 20 erkek birey dahil edilmiştir. Kafein alımını belirlemek için, deneyimli bir diyetisyen tarafından özel olarak geliştirilmiş kafein-besin alım sıklığı anketi uygulanmıştır. Bireyler kafein alımlarına göre 3 gruba ayrılmıştır; Grup 1: ≤150 mg/gün, Grup 2: 150-250 mg/gün ve Grup 3: ≥250 mg/gün. Antropometrik ölçümler ve biyokimyasal parametreler kaydedilmiştir. Serum örneklerindeki protein miktarları ELISA yöntemi ile belirlenmiştir.
Bulgular: Grup 1'in vücut yağ kompozisyonu grup 2'den daha yüksektir. Grup 3'ün alanin aminotransferaz (ALT) ve aspartat aminotransferaz (AST) düzeyleri sırasıyla grup 1'den ve grup 2'den daha yüksektir. Grup 3'ün yüksek yoğunluklu lipoprotein kolesterol (HDL-C) düzeyi grup 1 ve grup 2'den daha düşüktür. Toplam kafein alımı ile ALT düzeyi arasında pozitif bir ilişki vardır. Kafein alım grupları arasında serum protein düzeyleri açısından anlamlı bir farklılık yoktur. Ayrıca serum protein seviyeleri ile toplam kafein alımı arasında anlamlı bir korelasyon bulunmamıştır.
Sonuç: ≥250 mg/gün kafein alımı, NAYKH olan bireylerde ALT ve AST düzeylerini yükseltebilir ve HDL-C düzeyini düşürebilir.

Keywords

Non-alkolik yağlı karaciğer hastalığı, kafein, alanin aminotransferaz, aspartat aminotransferaz, yüksek yoğunluklu lipoprotein

Association between caffeine intake and liver biomarkers in non-alcoholic fatty liver disease

Abstract

Purpose: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver enzymes in developed countries. The aim of this study is to examine the effects of caffeine intake on some parameters of liver metabolism in individuals with NAFLD.
Materials and Methods: A total of 20 female and 20 male subjects between the ages of 19 to 64, who were diagnosed with NAFLD, were included in the study. To determine caffeine intake, a specially developed caffeine-food frequency questionnaire was administered by a trained dietitian. Individuals were categorized into 3 groups according to their caffeine intake; Group 1: ≤150 mg/day, Group 2: 150-250 mg/day, and Group 3: ≥250 mg/day. Anthropometric measurements and biochemical parameters were recorded. Protein quantities in serum samples were determined by ELISA method.
Results: The body fat composition of group 1 was higher than group 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of group 3 were higher than group 1 and group 2, respectively. High-density lipoprotein cholesterol (HDL-C) level of group 3 was lower than group 1 and group 2. There was a positive correlation between total caffeine intake and ALT level. There was no significant difference between the caffeine intake groups in terms of serum protein levels. In addition, there was not found significant correlation between serum protein levels and total caffeine intake.
Conclusion: Caffeine intake of ≥250 mg/day may increase ALT and AST levels and decrease HDL-C level in individuals with NAFLD.

Keywords

Non-alcoholic fatty liver disease, caffeine, alanine aminotransferase, aspartate aminotransferase, high-density lipoprotein

References

• Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593-608.
• Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D et al. Nonalcoholic fatty liver disease: a multisystem disease? World J Gastroenterol. 2016;22:9488-505.
• Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34:1250-8.
• Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 2012;57:1090-6.
• Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:76-82.
• Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol. 2014;29:435-41.
• Feld JJ, Lavoie EG, Fausther M, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res. 2015;4:95.
• Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res 2015. 165:428-36.
• Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-36.
• Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51:201-9.
• Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2010;55:3200-6.
• Saab S, Mallam D, Cox GA, 2nd, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34:495-504.
• Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr. 2006;46:101-23.
• Bonita JS, Mandarano M, Shuta D, Vinson J. Coffee and cardiovascular disease: In vitro, cellular, animal, and human studies. Pharmacol Res. 2007;55:187-98.
• Arab JP, Hernandez-Rocha C, Morales C, Vargas JI, Solis N, Pizarro M et al. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Gastroenterol Hepatol. 2017;40:388-94.
• Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother. 2005;59:S359-62.
• MacFarlane M, Merrison W, Dinsdale D, Cohen GM. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol. 2000;148:1239-54.
• Maher MM, Ibrahim WA, Saleh SA, Shash L, Abou H, Tarif M et al. Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egypt J Medical Hum Genet. 2015;16:41-6.
• Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012;56:1363-70.
• Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43.
• Liu J, Xu Y, Hu Y, Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64:380-90.
• Inagaki T. Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD. Front Endocrinol (Lausanne). 2015;6:147.
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
• Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2005;128:24-32.
• Honjo S, Kono S, Coleman MP, Shinchi K, Sakurai Y, Todoroki I et al. Coffee drinking and serum gamma-glutamyltransferase: an extended study of Self-Defense Officials of Japan. Ann Epidemiol. 1999;9:325-31.
• Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol. 1993;9:293-7.
• Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38:2552-7.
• Chung HK, Nam JS, Lee MY, Kim YB, Won YS, Song WJ et al. The increased amount of coffee consumption lowers the incidence of fatty liver disease in Korean men. Nutr Metab Cardiovasc Dis. 2020;30:1653-61.
• Scientific Opinion on the safety of caffeine. EFSA J. 2015;13:4102.
• Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57:372-7.
• Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther. 2007;26:1-8.
• Graeter T, Niedermayer PC, Mason RA, Oeztuerk S, Haenle MM, Koenig W et al. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes. 2015;8:640.
• Poyrazoglu OK, Bahcecioglu IH, Ataseven H, Metin K, Dagli AF, Yalniz M et al. Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. Inflammation. 2008;31:408-13.
• Wadhawan M, Anand AC. Coffee and Liver Disease. J Clin Exp Hepatol. 2016;6:40-6.
• Fukushima Y, Kasuga M, Nakao K, Shimomura I, Matsuzawa Y. Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets. J Agric Food. 2009;57:11100-5.
• Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010;52:1652-61.
• Choi EY, Park SY, Cho YO. Freeze-dried instant coffee can promote the activities of antioxidant enzymes and induce weight loss but also aggravate the plasma cholesterol profile in rats. Nutrition. 2011;27:1202-5.
• Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412-21.
• Baranova A, Schlauch K, Elariny H, Jarrar M, Bennett C, Nugent C et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg. 2007;17:1111-8.
• Berná G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. Liver Int. 2020;40:102-8.